MedTrace Logo

Dupilumab Phase 4 Study

NCT03411837 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2021-10-12

No results posted yet for this study

Summary

The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.

Conditions

Interventions

BIOLOGICAL

Dupilumab

Biologic (monoclonal antibody)

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2019-08-31
Completion
2019-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03411837 on ClinicalTrials.gov